Christopher Sayed, MD, a Dermatologist at the University of North Carolina Chapel Hill’s HS Clinic in Durham, NC, discusses the role that bimekizumab-bkzx may play for adults with moderate-to-severe hidradenitis suppurativa (HS) now that it has the U.S. Food and Drug Administration’s nod for this chronic inflammatory skin condition.
